| Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. | |
| | |
MedLine Citation:
|
PMID: 20722702 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Achievement of complete response (CR) is a new goal of therapy for multiple myeloma (MM). By sensitive methods, the depth of response can be measured even among the patients in CR. We used a sensitive real-time quantitative polymerase chain reaction by allele-specific primers (qASO-PCR) to assess the level of minimal residual disease (MRD) in bone marrow of 37 patients with myeloma who had achieved CR/near-to-CR after autologous or allogeneic stem cell transplantation (SCT). Allele-specific primers could be successfully designed for 86% of patients. Three to six months after autotransplantation, the PCR target was not detectable in 53% of patients (16/30 patients), and the respective figure after allotransplantation was 71% (5/7 patients); the median sensitivity of PCR assay was <0.002%. The proportion of patients without detectable PCR target was 22% of all autotransplanted patients. A threshold level of 0.01% in the qASO-PCR assay 3-6 months after SCT was found to be a useful cut-off limit to divide the patients into two prognostic groups: MRD low/negative vs. MRD high. Low/negative MRD after SCT was a significant predictive factor for the prolongation of progression free (70 vs. 19 months; P = 0.003) and suggestively also for overall survival. We conclude that not only CR but also its depth is important for the long-term outcome in MM. |
| | |
Authors:
|
Mervi Putkonen; Veli Kairisto; Vesa Juvonen; Tarja-Terttu Pelliniemi; Auvo Rauhala; Maija Itälä-Remes; Kari Remes |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: European journal of haematology Volume: 85 ISSN: 1600-0609 ISO Abbreviation: Eur. J. Haematol. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-22 Completed Date: 2010-12-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8703985 Medline TA: Eur J Haematol Country: England |
Other Details:
|
Languages: eng Pagination: 416-23 Citation Subset: IM |
Copyright Information:
|
© 2010 John Wiley & Sons A/S. |
Affiliation:
|
Department of Medicine, Turku University Central Hospital, Vaasa, Finland. mervi.putkonen@tyks.fi |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Alleles* Bone Marrow / pathology DNA Primers Disease-Free Survival Female Hematopoietic Stem Cell Transplantation / methods* Humans Male Middle Aged Multiple Myeloma / diagnosis*, mortality, therapy* Neoplasm, Residual / diagnosis* Polymerase Chain Reaction / methods*, standards Predictive Value of Tests* Prognosis Remission Induction / methods Sensitivity and Specificity Survival Rate Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/DNA Primers |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Longer survival associated with HLA-A*03, B*14 among 212 hemochromatosis probands with HFE C282Y hom...
Next Document: The incidence of traumatic brain injury in an adult population - how to classify mild cases?